|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项PT-112注射液单药治疗晚期实体瘤患者和晚期肝细胞癌患者的开放性I/II期临床研究
[Translation] An open-label phase I/II clinical study of PT-112 injection monotherapy in patients with advanced solid tumor and advanced hepatocellular carcinoma
剂量递增阶段 主要目的:评估PT-112注射液治疗晚期实体瘤患者的安全性和耐受性。 剂量确认阶段 主要目的:评估PT-112注射液以推荐最高安全剂量治疗晚期实体瘤患者的安全性和耐受性; II期试验阶段 主要目的:评估PT-112注射液以RP2D剂量治疗晚期肝细胞癌的抗肿瘤作用。
[Translation] Dose escalation phase Main objective: To evaluate the safety and tolerability of PT-112 injection in patients with advanced solid tumors. The main purpose of the dose confirmation phase: to evaluate the safety and tolerability of PT-112 injection in the treatment of patients with advanced solid tumors at the highest recommended safe dose; the main purpose of the phase II trial phase: to evaluate the RP2D dose of PT-112 injection in the treatment of advanced hepatocytes Antitumor effect of cancer.
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
The purpose of this study is to test PT-112 in Combination with Docetaxel in Subjects with Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects with Non-Small Cell Lung Cancer.
100 Clinical Results associated with SciClone Pharmaceuticals International (Cayman) Development Limited
0 Patents (Medical) associated with SciClone Pharmaceuticals International (Cayman) Development Limited
100 Deals associated with SciClone Pharmaceuticals International (Cayman) Development Limited
100 Translational Medicine associated with SciClone Pharmaceuticals International (Cayman) Development Limited